DDInter119 DDInter1258
Armodafinil is the enantiopure of the wakefulness-promoting agent modafinil (Provigil), and is indicated to improve wakefulness in adult patients with excessive sleepiness associated with obstructive sleep apnea (OSA), narcolepsy, or shift work disorder (SWD). Research has shown that armodafinil significantly improves driving simulator performance in patients with SWD. Armodafinil consists of the (−)-R-enantiomer of the racemic modafinil. Armodafinil is produced by the pharmaceutical company Cephalon Inc. (a wholly owned subsidiary of Teva Pharmaceutical Industries Ltd.) and was approved by the U.S. Food and Drug Administration (FDA) in June 2007.
Naldemedine is an opioid receptor antagonist [FDA Label]. It is a modified form of to which a side chain has been added to increase molecular weight and polar surface area resulting in restricted transport across the blood brain barrier. Naldemedine was approved in 2017 in both the US and Japan for the treatment of Opioid-induced Constipation.
Naldemedine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Modafinil
Naldemedine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Mifepristone
Naldemedine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Istradefylline
Naldemedine {u} may lead to a major life threatening interaction when taken with {v} Phenobarbital
Naldemedine {u} may lead to a major life threatening interaction when taken with {v} Apalutamide
Naldemedine may cause a minor interaction that can limit clinical effects when taken with Modafinil
Naldemedine may cause a moderate interaction that could exacerbate diseases when taken with Mifepristone
Naldemedine may cause a moderate interaction that could exacerbate diseases when taken with Istradefylline
Naldemedine may lead to a major life threatening interaction when taken with Phenobarbital
Naldemedine may lead to a major life threatening interaction when taken with Apalutamide